Sanofi shares drop nearly 3%, among the steepest declines in the CAC 40
The pharmaceutical group falls sharply mid-session, in a Parisian market trending lower after the correction in technology stocks on Wall Street. The stock posts one of the most pronounced declines in the index, after reaching a multi-month high this week.
A 2.92% decline that interrupts the rebound under way since October
Sanofi shares fall 2.92% to €82.06, among the steepest declines in the CAC 40, which drops 1.43% to 8,088.27 points. The stock had broken through its 150-session high of €82.03 on Wednesday, following the upward revision of its 2026 targets and a third quarter up 14.3% at constant exchange rates.
Today's decline comes amid strong tension, with the VIX at 26.39 versus 16.61 the previous day.
Despite this pullback, the stock remains 8.04% above its MM20 and 6.97% above its MM200, and shows a gain of 17.25% over one month. The RSI at 68 indicates a stock that has remained close to overbought territory after this rise.
A €120 target published today, against a P/E of 9.6
In this hesitant market, an analyst opinion was issued this Friday: Intron Health issued a buy rating with a price target of €120, representing a potential of nearly 46% relative to the current price. This target is significantly above the session's level.
According to the consensus of the analysts surveyed, the stock trades at around 9.6 times earnings for the current fiscal year and 9.1 times those of the following year, with expected earnings per share growth of 5.7%.
In terms of price benchmarks, the stock is trading near its resistance at €84.53, the previous day's closing level, while the nearest support is at €69.99.
